Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2022 Mar 30

PMID 35350436

Authors

Andrea R Thurman

Jacques Ravel

Pawel Gajer

Mark A Marzinke

Louise A Ouattara

Terry Jacot

M Melissa Peet

Meredith R Clark

Gustavo F Doncel

Affiliations

Soon will be listed here.

Abstract

Background: A relationship between the vaginal microbiota and tenofovir (TFV) concentrations and activity after topical administration has been previously reported.

Objective: CONRAD A15-138 was a randomized, placebo-controlled Phase I study aimed at characterizing the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TFV and levonorgestrel (LNG) administered through a vaginal ring (IVR) for 90 days. Herein, we describe changes from baseline in the vaginal microbiota with IVR use and the impact of the vaginal microbiota on mucosal TFV PK.

Methods: The study screened 68 participants and randomized 47 (37 TFV/LNG, 10 placebo), assessing the vaginal microbiota by sequencing the V3-V4 regions of 16S rRNA genes prior to IVR insertion and monthly for 3 months. Concentrations of TFV in vaginal fluid (VF), and TFV and TFV-diphosphate (TFV-DP) in vaginal tissue, and modeled PD against HIV-1 were measured before and after treatment.

Results: There were no clinically significant changes in relative abundance of vaginal bacterial phylotypes from pre-insertion baseline at any month among active and placebo IVR users. There were no significant changes in community state type (CST) with IVR use. Participants with diverse, anaerobic CST IVA/B microbiota had higher release of TFV from the IVR compared to women with -dominated (LbD) microbiota, who had expected TFV release rates. Median VF TFV concentrations were significantly higher among women with CST IVA/B microbiota in months 1 (3,135 ng/mg VF) and 2 (3,800 ng/mg). Women with LbD microbiota had significantly higher median VF TFV concentration (1,423 ng/mg) and median TFV (103 ng/mg) and TFV-DP (5,877 fmol/mg) tissue concentrations versus women with CST IVA/B microbiota at month 3. All women demonstrated a significant increase from pre-insertion baseline of HIV-1 inhibition by VF (p values <0.05). PD differences in tissue according to CST, however, were not statistically significant.

Conclusion: TFV/LNG IVR use did not change the vaginal microbiota nor increase the incidence of CST IVA/B. Vaginal microbiota, and in particular CST IVA/B, possibly through increased vaginal pH, impacted TFV release and cervicovaginal (CV) PK, but both PK and PD data suggest CV protection against HIV-1.

Clinical Trial Registration: ClinicalTrials.gov (#NCT03279120).

Citing Articles

The role of pharmacomicrobiomics in HIV prevention, treatment, and women's health.

Swanson E, Basting C, Klatt N Microbiome. 2024; 12(1):254.

PMID: 39627860 PMC: 11613800. DOI: 10.1186/s40168-024-01953-3.

Longitudinal cervicovaginal microbiome and virome alterations during ART and discordant shedding in women living with HIV.

Kaelin E, Mitchell C, Soria J, La Rosa A, Ticona E, Coombs R Res Sq. 2024; .

PMID: 38699319 PMC: 11065064. DOI: 10.21203/rs.3.rs-4078561/v1.

Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.

Liu A, Gundacker H, Richardson B, Chen B, Hoesley C, van der Straten A J Int AIDS Soc. 2024; 27(3):e26223.

PMID: 38444118 PMC: 10935712. DOI: 10.1002/jia2.26223.

Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.

Lantz A, Cottrell M, Corbett A, Chinula L, Kourtis A, Nelson J AIDS. 2023; 37(14):2185-2190.

PMID: 37877275 PMC: 10605758. DOI: 10.1097/QAD.0000000000003686.

Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.

Mugo N, Mudhune V, Heffron R, Thomas K, McLellan-Lemal E, Njoroge B Front Reprod Health. 2023; 5:1118030.

PMID: 37383290 PMC: 10293630. DOI: 10.3389/frph.2023.1118030.

References

Hoffman M, Bellad M, Charantimath U, Kavi A, Nagmoti J, Nagmoti M . A Comparison of Colorimetric Assessment of Vaginal pH with Nugent Score for the Detection of Bacterial Vaginosis. Infect Dis Obstet Gynecol. 2017; 2017:1040984. PMC: 5331313. DOI: 10.1155/2017/1040984. View

Clark J, Clark M, Shelke N, Johnson T, Smith E, Andreasen A . Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS One. 2014; 9(3):e88509. PMC: 3943718. DOI: 10.1371/journal.pone.0088509. View

Teunissen A, Grimm B, Roumen F . Continuation rates of the subdermal contraceptive Implanon(®) and associated influencing factors. Eur J Contracept Reprod Health Care. 2013; 19(1):15-21. DOI: 10.3109/13625187.2013.862231. View

Johnson T, Clark M, Albright T, Nebeker J, Tuitupou A, Clark J . A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother. 2012; 56(12):6272-83. PMC: 3497207. DOI: 10.1128/AAC.01431-12. View

Dabee S, Mugo N, Mudhune V, McLellan-Lemal E, Peacock S, OConnor S . Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya. Sci Rep. 2022; 12(1):12040. PMC: 9283538. DOI: 10.1038/s41598-022-13475-9. View

Thurman A, Schwartz J, Ravel J, Gajer P, Marzinke M, Yousefieh N . Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. PLoS One. 2019; 14(5):e0217229. PMC: 6527208. DOI: 10.1371/journal.pone.0217229. View

De Seta F, Restaino S, De Santo D, Stabile G, Banco R, Busetti M . Effects of hormonal contraception on vaginal flora. Contraception. 2012; 86(5):526-9. DOI: 10.1016/j.contraception.2012.02.012. View

Roumen F, Boon M, van Velzen D, Dieben T, Coelingh Bennink H . The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring. Hum Reprod. 1996; 11(11):2443-8. DOI: 10.1093/oxfordjournals.humrep.a019134. View

Balkus J, Richardson B, Rabe L, Taha T, Mgodi N, Kasaro M . Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis. 2014; 41(2):123-8. PMC: 4128240. DOI: 10.1097/OLQ.0000000000000075. View

10.

Mitra A, MacIntyre D, Marchesi J, Lee Y, Bennett P, Kyrgiou M . The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?. Microbiome. 2016; 4(1):58. PMC: 5088670. DOI: 10.1186/s40168-016-0203-0. View

11.

Sanu O, Lamont R . Periodontal disease and bacterial vaginosis as genetic and environmental markers for the risk of spontaneous preterm labor and preterm birth. J Matern Fetal Neonatal Med. 2011; 24(12):1476-85. DOI: 10.3109/14767058.2010.545930. View

12.

Kestelyn E, Agaba S, Van Nuil J, Uwineza M, Umulisa M, Mwambarangwe L . A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use. PLoS One. 2018; 13(6):e0197572. PMC: 5983532. DOI: 10.1371/journal.pone.0197572. View

13.

Taneva E, Sinclair S, Mesquita P, Weinrick B, Cameron S, Cheshenko N . Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. JCI Insight. 2018; 3(13). PMC: 6124523. DOI: 10.1172/jci.insight.99545. View

14.

Cohen R, Sheeder J, Teal S . Predictors of Discontinuation of Long-Acting Reversible Contraception Before 30 Months of Use by Adolescents and Young Women. J Adolesc Health. 2019; 65(2):295-302. DOI: 10.1016/j.jadohealth.2019.02.020. View

15.

Richardson-Harman N, Lackman-Smith C, Fletcher P, Anton P, Bremer J, Dezzutti C . Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol. 2009; 47(11):3530-9. PMC: 2772583. DOI: 10.1128/JCM.00673-09. View

16.

Hendrix C, Andrade A, Bumpus N, Kashuba A, Marzinke M, Moore A . Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2015; 32(1):32-43. PMC: 4692123. DOI: 10.1089/AID.2015.0182. View

17.

Callahan B, McMurdie P, Rosen M, Han A, Johnson A, Holmes S . DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016; 13(7):581-3. PMC: 4927377. DOI: 10.1038/nmeth.3869. View

18.

Wei X, Decker J, Liu H, Zhang Z, Arani R, Michael Kilby J . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905. PMC: 127242. DOI: 10.1128/AAC.46.6.1896-1905.2002. View

19.

Thurman A, Doncel G . Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol. 2010; 65(2):89-98. DOI: 10.1111/j.1600-0897.2010.00902.x. View

20.

Bushman L, Kiser J, Rower J, Klein B, Zheng J, Ray M . Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011; 56(2):390-401. PMC: 3153375. DOI: 10.1016/j.jpba.2011.05.039. View